216 related articles for article (PubMed ID: 22619076)
21. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.
Woolfson AD; Malcolm RK; Morrow RJ; Toner CF; McCullagh SD
Int J Pharm; 2006 Nov; 325(1-2):82-9. PubMed ID: 16884869
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic evaluation of tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed macaques after 6 months of continuous use.
Srinivasan P; Dinh C; Zhang J; Pau CP; McNicholl JM; Lo Y; Herold BC; Teller R; Kiser P; Smith JM
J Med Primatol; 2014 Oct; 43(5):364-9. PubMed ID: 25379594
[TBL] [Abstract][Full Text] [Related]
23. Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.
Gunaseelan S; Gallay PA; Bobardt MD; Dezzutti CS; Esch T; Maskiewicz R
Pharm Res; 2012 Nov; 29(11):3156-68. PubMed ID: 22736232
[TBL] [Abstract][Full Text] [Related]
24. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
[TBL] [Abstract][Full Text] [Related]
25. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir.
Johnson TJ; Gupta KM; Fabian J; Albright TH; Kiser PF
Eur J Pharm Sci; 2010 Feb; 39(4):203-12. PubMed ID: 19958831
[TBL] [Abstract][Full Text] [Related]
26. Controlling the hydration rate of a hydrophilic matrix in the core of an intravaginal ring determines antiretroviral release.
Teller RS; Malaspina DC; Rastogi R; Clark JT; Szleifer I; Kiser PF
J Control Release; 2016 Feb; 224():176-183. PubMed ID: 26723526
[TBL] [Abstract][Full Text] [Related]
27. An evaluation of polycaprolactone matrices for vaginal delivery of the antiviral, tenofovir, in preventing heterosexual transmission of HIV.
Dang NT; Sivakumaran H; Harrich D; Coombes AG
J Pharm Sci; 2013 Oct; 102(10):3725-35. PubMed ID: 23904196
[TBL] [Abstract][Full Text] [Related]
28. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
Ham AS; Ugaonkar SR; Shi L; Buckheit KW; Lakougna H; Nagaraja U; Gwozdz G; Goldman L; Kiser PF; Buckheit RW
J Pharm Sci; 2012 Apr; 101(4):1423-35. PubMed ID: 22227864
[TBL] [Abstract][Full Text] [Related]
29. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.
Mesquita PM; Rastogi R; Segarra TJ; Teller RS; Torres NM; Huber AM; Kiser PF; Herold BC
J Antimicrob Chemother; 2012 Jul; 67(7):1730-8. PubMed ID: 22467632
[TBL] [Abstract][Full Text] [Related]
30. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Karim QA; Kharsany AB; Frohlich JA; Baxter C; Yende N; Mansoor LE; Mlisana KP; Maarschalk S; Arulappan N; Grobler A; Sibeko S; Omar Z; Gengiah TN; Mlotshwa M; Samsunder N; Karim SS
Trials; 2011 Mar; 12():67. PubMed ID: 21385354
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Abdool Karim SS; Abdool Karim Q; Kharsany AB; Baxter C; Grobler AC; Werner L; Kashuba A; Mansoor LE; Samsunder N; Mindel A; Gengiah TN;
N Engl J Med; 2015 Aug; 373(6):530-9. PubMed ID: 26244306
[TBL] [Abstract][Full Text] [Related]
32. Design of tenofovir-UC781 combination microbicide vaginal gels.
Kiser PF; Mahalingam A; Fabian J; Smith E; Damian FR; Peters JJ; Katz DF; Elgendy H; Clark MR; Friend DR
J Pharm Sci; 2012 May; 101(5):1852-64. PubMed ID: 22359356
[TBL] [Abstract][Full Text] [Related]
33. Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet tablet containing a single excipient.
Mcconville C; Friend DR; Clark MR; Malcolm K
J Pharm Sci; 2013 Jun; 102(6):1859-1868. PubMed ID: 23568749
[TBL] [Abstract][Full Text] [Related]
34. Thermosensitive hydrogel of hydrophobically-modified methylcellulose for intravaginal drug delivery.
Li N; Yu M; Deng L; Yang J; Dong A
J Mater Sci Mater Med; 2012 Aug; 23(8):1913-9. PubMed ID: 22569735
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques.
Pereira LE; Clark MR; Friend DR; Garber DA; McNicholl JM; Hendry RM; Doncel GF; Smith JM
Antimicrob Agents Chemother; 2014 May; 58(5):2665-74. PubMed ID: 24566178
[TBL] [Abstract][Full Text] [Related]
36. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women.
Nel A; Smythe S; Young K; Malcolm K; McCoy C; Rosenberg Z; Romano J
J Acquir Immune Defic Syndr; 2009 Aug; 51(4):416-23. PubMed ID: 19623693
[TBL] [Abstract][Full Text] [Related]
37. AIDS: Drugs that prevent HIV infection.
Wainberg MA
Nature; 2011 Jan; 469(7330):306-7. PubMed ID: 21248832
[No Abstract] [Full Text] [Related]
38. Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.
Dang NT; Sivakumaran H; Harrich D; Shaw PN; Davis-Poynter N; Coombes AG
Eur J Pharm Biopharm; 2014 Oct; 88(2):406-14. PubMed ID: 24887313
[TBL] [Abstract][Full Text] [Related]
39. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Zhu Y; Curtis M; Qi X; Miller MD; Borroto-Esoda K
Antivir Chem Chemother; 2009; 19(4):165-76. PubMed ID: 19374144
[TBL] [Abstract][Full Text] [Related]
40. After CAPRISA 004: time to re-evaluate the HIV lexicon.
Cates W
Lancet; 2010 Aug; 376(9740):495-6. PubMed ID: 20709216
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
